The world, keenly waiting for a vaccine to defeat the coronavirus disease (Covid-19), might just be able to turn a corner with Oxford University’s candidate showing promising results. This could signal relief for ravaged economies and overworked healthcare systems in major nations battling the viral contagion that has claimed 1.15 million lives.
According to British and Swedish drugmaker AstraZeneca Plc, the drug AZD1222 has shown immune response in older and younger adults, with reduced adversarial effects among the elderly. Officials from the vaccine developer have said that it is ‘encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher’.
“The results further build the body of evidence for the safety and immunogenicity of AZD1222,” an AstraZeneca spokesperson said.
More info visit: https://immunology-vaccines.heraldmeetings.com/